伊鲁阿克是中国自主研发的新型ALK-TKI,2023年6月27日,国家药品监督管理局批准伊鲁阿克上市,用于既往接受过克唑替尼治疗后疾病进展或对克唑替尼不耐受的ALK融合基因阳性局部晚期或转移性NSCLC患者的治疗,2024年1月16日,国家药品监督管理局批准...
ALK融合突变是NSCLC的一类独特的分子亚型,何雅億教授指出,ALK阳性NSCLC患者的中位发病年龄较轻(约40岁),多数无吸烟史,确诊时多已处于晚期阶段,常伴有远处转移,传统化疗对其疗效有限,而ALK-TKI的出现为患者以及临床医生带来了新的希望。 当前,临床上的ALK-TKI可分为三代。克唑替尼作为第一代ALK-TKI开启了ALK阳性N...
在肺癌中,非小细胞肺癌(NSCLC)约占85%,由于发病隐匿,超过60%的NSCLC患者在诊断时已是局部晚期或发生转移[1]。在晚期NSCLC患者中,间变性淋巴瘤激酶(ALK)融合基因是重要的治疗靶点,对于ALK阳性晚期NSCLC患者,随着靶向药物的迭代研发和获批上市,患者的...
Kwak等[9]在2010年报道了克唑替尼治疗ALK阳性晚期NSCLC患者的I期临床研究结果,结果显示,82例ALK阳性晚期NSCLC患者的中位治疗时间为6.4个月,客观缓解率(objectiveresponserate,ORR)为57%,疾病控制率(diseasecontrolrate,DCR)为90%,6个月的无进展生存(progressfreesurvival,PFS)率为72%,且不良反应轻微。基于该研究结...
All ALK-positive and ALK-negative controls had advanced NSCLC. ALK-positive patients treated with crizotinib had a one-year overall survival rate of 74% and a two-year overall survival rate of 54%. Median overall survival had not been reached. This compared with outcomes for the ALK...
前言 尽管近年来死亡率有所下降,肺癌仍然是我国癌症死亡的主要原因。间变性淋巴瘤激酶(ALK)重排(融合)约占非小细胞肺癌(NSCLC)的5%。由于生存期显著优于化疗,在过去的...
17、Mazieres J, Iadeluca L, Shaw A, et al. MA11. 08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC[J]. Journal of Thoracic Oncology, 2021, 16(3): S175-S176.18、He L, Dar A C. Targeting drug-resistant...
(Value-Baseline)/Baseline. The survival rate was calculated using the formula: (Cell number at 96 h)/(Cell number at 0 h) × 100. Relative cell growth was calculated by (survival rate)−100. The freezing and thawing procedure had a negligible effect on CellTiter-Glo luminescence...
3、Liang H, Song X, Zhang Y, et al. Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study[J]. Thoracic Cancer, 2019, 10(7): 1521-1532. ...
与克唑替尼相比,未经治疗的ALK阳性晚期NSCLC患者获得了更大的临床益处,具有更高的ORR和潜在的更长的PFS,这一临床获益效果与EML4::ALK变体或ALK突变、TP53突变或旁路耐药改变无关。 SCI 19 August 2023 Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer ...